ARNA
Arena Falters on Belviq EU Approval
http://finance.yahoo.com/news/arena-falters-belviq-eu-approval-230849432.html;_ylt=AvF.buFHt5bFeo_uoFt58vCiuYdG;_ylu=X3oDMTIxbzQ4OG80BG1pdANXaWRlIFF1b3RlcyBNb2R1bGUEcG9zAzI3BHNlYwNNZWRpYVJlY2VudFF1b3Rlc1BvcnRmb2xpb3NXaWRl;_ylg=X3oDMTFpNzk0NjhtBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDBHBzdGNhdANob21lBHB0A3NlY3Rpb25z;_ylv=3
no, ni idea sobre CLSN y ANAC
Amarin Announces First Notification of U.S. Patent Allowance Based on ANCHOR Clinical Trial Results
http://finance.yahoo.com/news/amarin-announces-first-notification-u-162811200.html
Sobre AMRN
http://www.redacre.com/insights/2013/jan/23/amarin-anchor-patent-allowed-and-us-launch#.UQBHR9GgtLs.twitter
"We believe that the company may be issuing a press release tonight or tomorrow to announce the US availability of Vascepa."
"Within the next few days, possibly as soon as this evening, AMRN will issue a press release announcing US availability of Vascepa"
"Depending on how the initial script numbers come in, AMRN stock will either begin a gradual recovery to the $10 - $12 range or drift lower to the $7 - $5 range over the next two months."
no sé si valdrá para algo, pero en facebook ya hay campaña para darse de baja y no mantener a taaaanto gente de esta
https://www.facebook.com/events/324935577621286/
casualidad o no, la empresa encargada de gestionar lo de las recetas para el gobierno, telefónica
efectivamente estos se suela dar mucho a menudo, con la peculiaridad que se dan en todas las empresas sean del sector q (o casi todas)
por lo que pienso que tienen que sera fondos o algo a´sí
-------------Upgrades--------
----Peregrine Pharmaceuticals (NASDAQ: PPHM) was upgraded by analysts at Roth Capital from a "neutral" rating to a "buy" rating. They now have a $2.70 price target on the stock. 100.0% Upside.
----
otra pharma mas que inicia andadura en hepatitis C
es de OTC, Aethlon Medical (OTC: AEMD)
http://theotcinvestor.com/aethlon-medical-discloses-submission-of-hepatitis-c-virus-hcv-ide-to-fda-1629/